Can PRP Injections Match Vaginal Estrogen for GSM?

PRP has a real early signal, but it has not replaced vaginal estrogen

For postmenopausal women with genitourinary syndrome of menopause (GSM), intravaginal platelet-rich plasma (PRP) has moved beyond the usual regenerative-medicine fog of cell studies and testimonials. A 2025 randomized trial found that three PRP injection sessions produced improvements in sexual function and vaginal health in the same range as 12 weeks of vaginal estriol. That finding matters most for women who cannot use estrogen or prefer to avoid it.

It does not establish that PRP is statistically equivalent to estriol, that it works indefinitely, or that every clinic's PRP protocol will produce the same result. Those are separate questions, and the current evidence does not answer them.

GSM includes vaginal dryness, thinning and reduced resilience of vaginal tissue, pain with sex, and urinary symptoms. It tends to become more common as menopause progresses. In a longitudinal Chinese cohort, moderate or severe GSM rose from 23.9% in early menopausal transition to 71.4% by postmenopause stage +2. The 2025 cohort study by Fan et al. describes a persistent problem, not a short-lived nuisance.

The best comparison so far: PRP versus estriol

Sacarin et al.'s 2025 randomized controlled trial enrolled postmenopausal women aged 50 to 65 with follicle-stimulating hormone above 30 IU/L and a baseline Female Sexual Function Index (FSFI) score of 23 or lower. Participants received either three intravaginal PRP sessions at weeks 0, 4, and 8, or estriol 0.5 mg vaginal ovules twice weekly for 12 weeks.

The PRP protocol used 5 mL of autologous PRP, prepared through two centrifugation steps to reach roughly four to five times the participant's baseline platelet concentration. Clinicians injected it into the anterior and lateral vaginal walls with a 22-gauge blunt-tip cannula. The primary endpoint was change in total FSFI score at 12 weeks. The PRP group improved by 10.1 points; vaginal health index (VHI) improvement was comparable between the two groups at 12 weeks.

Those results support a cautious descriptive statement: in this trial, PRP performed in the same neighborhood as estriol. They do not prove non-inferiority in the formal statistical sense, because the trial did not use a prespecified non-inferiority analysis. The available study description also does not report a confidence interval for the 10.1-point PRP change or a between-group effect estimate. That leaves readers unable to judge the precision of the comparison from this result alone.

Another direct comparison points in the same direction. Atlihan et al.'s 2025 study compared PRP injections with topical estrogen in postmenopausal vaginal atrophy. Differences in the PRP procedures and outcome protocols prevent meaningful pooling with Sacarin et al., but two independent controlled comparisons against local estrogen are more informative than one.

Why PRP might help—and why mechanism is not proof

PRP concentrates platelets from a person's own blood. Activated platelets release signaling molecules including platelet-derived growth factor, transforming growth factor beta (TGF-beta), and vascular endothelial growth factor. These molecules can support cell proliferation, collagen remodeling, and blood-vessel formation.

There is tissue-specific laboratory support for that hypothesis. Berndt et al. studied vaginal fibroblasts from postmenopausal women in vitro and found that autologous PRP improved their regenerative potential, with TGF-beta-related collagen remodeling as a plausible pathway. A broader 2025 review of PRP mechanisms also describes PDGF, TGF-beta, and VEGF signaling across tissues.

Cells in a dish do not establish that injected PRP rebuilds vaginal mucosa in living people. The laboratory findings make the clinical result biologically plausible; they do not tell us how durable the benefit is, which preparation works best, or whether collagen remodeling explains the patient-reported changes.

What the evidence says for cancer survivors

Women with hormone-sensitive cancer often have the most pressing need for non-hormonal GSM treatment. The evidence here needs unusually careful wording.

In a prospective controlled comparison of cancer survivors with vulvovaginal atrophy, Omar et al. in 2023 compared submucosal PRP alone with PRP plus non-crosslinked hyaluronic acid (HA). The groups had comparable FSFI improvements. This supports standalone PRP as a candidate treatment in that population; it does not compare PRP with estrogen or demonstrate that adding HA improves sexual function.

Chen et al.'s 2025 breast-cancer-survivor study provides the longest follow-up cited here: six months after PRP injections to the vaginal wall and posterior fourchette. But it was a safety and feasibility study, not a powered efficacy trial. Its value is the safety and feasibility signal, not proof that PRP improves GSM symptoms in breast cancer survivors.

How does PRP compare with hyaluronic acid?

HA injections offer another hormone-free injectable approach. In postmenopausal women with vulvovaginal atrophy, Ragy et al. in 2025 compared HA injections with PRP and found PRP performed at least comparably to HA. The study did not establish PRP superiority.

PRP and HA have different proposed biological roles. HA mainly provides hydration and tissue support, while PRP adds growth factors that may influence repair signaling. That distinction is interesting, but no controlled long-term trial has shown that it produces a larger or more durable clinical benefit than HA.

The central problem: "PRP" is not one standardized treatment

The evidence is encouraging but hard to combine. Moccia et al.'s 2024 systematic review found substantial variation among injection studies in PRP preparation, platelet concentration, injection volume, anatomical targets, and outcome measures. Sacarin et al. used 5 mL of PRP with a target concentration four to five times baseline. Other reports use different concentrations, activators, and injection techniques.

That variability matters in practice. A patient cannot assume that a procedure sold as "vaginal PRP" matches the protocol studied in the trial. It also prevents a reliable pooled estimate of effect across studies. The field needs standardized preparation and injection methods before anyone can speak confidently about a class-wide treatment effect.

The index trial has its own limitations. Participants could not realistically be blinded to injections versus vaginal ovules, so expectation effects may have influenced the patient-reported FSFI outcome. The reported description does not clearly specify the randomization or allocation-concealment method. Follow-up ended at 12 weeks, participants with hormone-sensitive cancer were excluded, and the study took place in three private Romanian gynecology centers. These features limit certainty and generalizability.

Fat grafting plus PRP is a different intervention

Autologous fat grafting plus PRP may be where the field is experimenting next, but it should not be folded into the evidence for outpatient intravaginal PRP. Ren et al.'s 2026 retrospective case series included 38 women and combined liposuction, fat processing, multi-site injections to areas including the mons pubis and labia majora, PRP, and dexamethasone. The primary outcome was vaginal laxity questionnaire score at six months.

The study had no control group, randomization, or blinding. It was originally planned as a prospective cohort but was analyzed retrospectively, and its sample-size calculation applied to vaginal laxity rather than FSFI subscales. The procedure is more invasive than office-based intravaginal PRP, so its findings are preliminary and cannot confirm an effect on sexual function or GSM.

What to do with this now

Vaginal estrogen remains a widely used first-line hormonal treatment for GSM. PRP is a reasonable topic for discussion with a gynecologist when estrogen is unsuitable or unwanted, particularly for a patient seeking a hormone-free injectable option. It has early controlled evidence, including one randomized estriol comparison with a 10.1-point FSFI improvement in the PRP arm at 12 weeks.

Patients should ask exactly how the PRP will be prepared, where it will be injected, what follow-up the clinic offers, and what evidence supports that specific protocol. No trial in this evidence base reports PRP outcomes beyond six months, and no study establishes an optimal repeat-treatment schedule. For a chronic condition, that missing durability data is the part that should keep expectations honest.